Cargando…

Repigmentation and new growth of hairs after anti–interleukin-17 therapy with secukinumab for psoriasis

Detalles Bibliográficos
Autores principales:	Rongioletti, Franco, Mugheddu, Cristina, Murgia, Severino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031562/ https://www.ncbi.nlm.nih.gov/pubmed/29984292 http://dx.doi.org/10.1016/j.jdcr.2018.01.006

Ejemplares similares

Vitiligo with Progressive Repigmentation during Secukinumab Treatment in a Patient with Psoriatic Arthritis: A Case Report
por: Giordano, Domenico, et al.
Publicado: (2021)

Image Gallery: Green moss‐like psoriasis
por: Rongioletti, F., et al.
Publicado: (2019)

Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis
por: Godse, Kiran
Publicado: (2017)

Hair repigmentation associated with the use of brentuximab
por: Penzi, Lauren R., et al.
Publicado: (2017)

Hair repigmentation in microcystic adnexal carcinoma
por: Saal, Ryan C., et al.
Publicado: (2023)

Secukinumab: The Anti-IL-17A Biologic for the Treatment of Psoriasis
por: Fargnoli, Maria Concetta
Publicado: (2019)

Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
por: Feng, Zhaorui, et al.
Publicado: (2023)

Interleukin-17A-Correlated Myocarditis in Patients with Psoriasis: Cardiac Recovery following Secukinumab Administration
por: Frustaci, Andrea, et al.
Publicado: (2023)

Repigmentation of gray hairs with lentigo maligna and response to topical imiquimod
por: Lackey, Alexandra E., et al.
Publicado: (2019)

Interleukin-17A Inhibitor Secukinumab Treatment in HIV-Positive Psoriasis Patient: A Case Report
por: Gong, Jian, et al.
Publicado: (2022)

The First Case of Ustekinumab-Associated Hair Repigmentation and a Proposed Mechanism of Action
por: Park, Su Jung, et al.
Publicado: (2021)

Cerebrolysin induces hair repigmentation associated to MART-1/Melan-A reactivation
por: Villarreal-Reyna, Gustavo, et al.
Publicado: (2022)

A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
por: Eshwar, Vishnu, et al.
Publicado: (2022)

Secukinumab in Generalized Pustular Psoriasis
por: Madanagobalane, Shraddha
Publicado: (2018)

Refractory Psoriasis Vulgaris with Itching Successfully Treated with the Anti-interleukin-17A Antibody Secukinumab: A Case of Secondary Failure of Other Biologic Agents
por: Kurosaki, Yuko, et al.
Publicado: (2017)

Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study
por: Pellegrini, Cristina, et al.
Publicado: (2022)

Control of porphyria cutanea tarda with anti-IL-17 secukinumab in a person with psoriasis living with HIV
por: Bedier, Helbies, et al.
Publicado: (2023)

Cyclosporine A-induced Hair Repigmentation in a Patient with Dermatitis: A Case Report
por: Al Rajaibi, Raqiya, et al.
Publicado: (2023)

Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis
por: PHAN, Céline, et al.
Publicado: (2020)

Successful use of secukinumab in pustular psoriasis
por: Yeung, Jensen, et al.
Publicado: (2016)

Repigmentation of Tenacious Vitiligo on Apremilast
por: Huff, Sara B., et al.
Publicado: (2017)

Alopecia Areata After Initiation of Secukinumab Therapy for Plaque Psoriasis
por: Choi, Esther, et al.
Publicado: (2023)

Profile of secukinumab in the treatment of psoriasis: current perspectives
por: Roman, Michael, et al.
Publicado: (2015)

Secukinumab in the treatment of psoriasis: patient selection and perspectives
por: Yang, Eric J, et al.
Publicado: (2018)

Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy
por: Gambardella, Alessio
Publicado: (2019)

Repigmentation of Eyebrow Leukotrichia in Segmental Vitiligo Treated with Suction Blister Epidermal Grafting Following Hair Plucking
por: Oh, Se Jin, et al.
Publicado: (2019)

Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy
por: Gisondi, Paolo, et al.
Publicado: (2014)

Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study
por: COSTANZO, Antonio, et al.
Publicado: (2021)

Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study
por: TALAMONTI, Marina, et al.
Publicado: (2021)

Targeting of interleukin-17 in the treatment of psoriasis
por: Lønnberg, Ann Sophie, et al.
Publicado: (2014)

Interleukin-17A and Keratinocytes in Psoriasis
por: Furue, Masutaka, et al.
Publicado: (2020)

Assessment of serum biomarkers in patients with plaque psoriasis on secukinumab
por: Morita, Akimichi, et al.
Publicado: (2020)

Efficacy of Secukinumab for Plaque Psoriasis in a Patient on Hemodialysis
por: Ikuma, Daiuske, et al.
Publicado: (2019)

Secukinumab for psoriasis in a patient with familial Mediterranean fever
por: Cannavò, Serafinella P., et al.
Publicado: (2019)

Secukinumab for Psoriasis in Obese Patients: Minireview and Clinical Experience
por: Tiberio, Rossana, et al.
Publicado: (2019)

Behandlung der Psoriasis mit Secukinumab: Praxisrelevante Hinweise
por: Körber, Andreas, et al.
Publicado: (2021)

Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability
por: Narbutt, Joanna, et al.
Publicado: (2023)

Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study
por: Avallone, Gianluca, et al.
Publicado: (2023)

Hair repigmentation and regrowth in a dupilumab-treated paediatric patient with alopecia areata and atopic dermatitis: a case report
por: Yan, Xin, et al.
Publicado: (2023)

Atypical oral candidiasis in a psoriatic patient during targeted immunotherapy with an interleukin 17 inhibitor (secukinumab)
por: Picciani, Bruna Lavinas Sayed, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1qg3bk3l6b6nue4k2d7okr8muh